Navigation Links
Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
Date:8/31/2011

ZURICH, Switzerland, September 1, 2011 /PRNewswire/ --

Study Assessing the Safety and Efficacy of KUR-211 Expected to Report in mid 2012

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed recruitment in a Phase IIb clinical trial designed to investigate KUR-211 (Viz.I-020201) in the treatment of diabetic foot ulcers.

This Phase IIb clinical trial is a randomised, multi-center, controlled, parallel group dose-finding study to evaluate the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcers. KUR-211 is a bioactive therapy intended for topical treatment of diabetic foot ulcers, stimulating the granulation tissue formation, that aids wound closure. The study evaluates the effects of KUR-211 applied twice a week for maximum 16 weeks in addition to standard of care versus standard of care (SOC) alone.

KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and is applied to the wound as a foam. The innovative Kuros "TG-hook" technology enables the PDGF to be retained at the site for local exposure to migrating cells and for sustained delivery of PDGF on enzymatic cleavage of the matrix. It is believed that this novel approach may improve the frequency and speed of healing.

A total of 211 patients have been randomized and treated in over 27 centers across Europe including Russia. The primary endpoint of this study is percentage reduction in ulcer surface area after 4 weeks of treatment when compared to SOC alone.  Patients are followed for 7 months following initial treatment. Kuros is expecting to report the outcome of this study around the middle of 2012.

Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: "We are very pleased t
'/>"/>

SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
6. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
9. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
10. Roche completes acquisition of ARIUS
11. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 ... ancestry tracing for people of African descent, today ... product offering. For people of all races, myDNAmix ... from five distinct populations: Indigenous Americas (Native American), ... India Subcontinent. , Originally launched in ...
(Date:5/23/2013)... St. Louis, Missouri (PRWEB) May 23, 2013 ... design and manufacture of complete thermal systems, recently ... more than 90 years of experience in designing ... most complete selection of products to serve diverse ... lead-time options is featured at the beginning of ...
(Date:5/22/2013)... 22, 2013 Oven Industries announces the ... integrated potentiometers or via a PC through the TTL ... and one half inches square can deliver up to ... switched, low noise solid state relay. Operator safety is ... the communication port and sensor input. Specifications: Input ...
(Date:5/22/2013)... Boston, MA (PRWEB) May 22, 2013 ... to present at last week’s “Data Demonstration Day” on Capitol ... Cambridge Semantics joined EMC, Google, Microsoft and others to showcase ... the proposed Digital Accountability and Transparency Act (DATA Act). , ... Darrell Issa (R-CA) and Sen. Mark ...
Breaking Biology Technology:AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Watlow Introduces Its New Industrial Heater Catalog 2New AC Temperature Controller Announced by Oven Industries 2Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2
... Jan. 26 WellCentive, LLC,today announced that WellCentive ... Information Exchange) as its patient registry and disease,management ... use of WellCentive Registry, more than 1,000 my1HIE ... will be better able to,provide preventive care services ...
... Jan. 26 Sirion Therapeutics, Inc., a privately held ... Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been ... Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... caused by the herpes simplex virus. The FDA has ...
... YORK, Jan. 26 Netsmart Technologies, Inc., a ... health and human services organizations, today announced it ... the New York State Association of Alcoholism and ... company,s comprehensive education, online learning and learning management ...
Cached Biology Technology:my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/22/2013)... CITY, May 22, 2013 U.S. Forest Service scientists ... that, with funding from the TKF Foundation, will examine ... communities and individuals recover from tragedy. , The TKF ... of six projects selected for grant funding. In addition ... sacred spaces in recovery and resiliency, the 3-year, $585,000 ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 19 2011) Bone marrow-derived stem cells (BMDCs) have been ... to different cell populations in a variety of organs under ... aimed at repairing damaged brain tissue or helping to restore ... to the cerebellum at the back of the brain. In ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
... (IRSF) announced today that it is awarding over $1.5M to ... diverse topics from basic science and disease pathology to developing ... the world,s largest private source of funding for biomedical and ... spending of over $26M since 1998. It is the ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
Biology Products: